Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00827554

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

A Clinical Randomized Control Trial of Combination TACE With and Without Low-molecular-weight Heparin in Hepatocellular Carcinoma

Sponsor: Eastern Hepatobiliary Surgery Hospital

Conditions Hepatocellular Carcinoma

Interventions LMWH TACE

Updated 6 times since 2017 Last updated: Mar 30, 2016 Started: Dec 31, 2008 Primary completion: Aug 31, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Hepatocellular Carcinoma, this trial is completed. The trial is conducted by Eastern Hepatobiliary Surgery Hospital and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Hepatobiliary Surgery Hospital

Data source: Eastern Hepatobiliary Surgery Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China